Mikhael F. El-Chami

Jun 30, 2024 | jamanetwork.com | Jonathan P. Piccini |Mikhael F. El-Chami |George H. Crossley |Kael Wherry

Key PointsQuestion  How do the performance of leadless VVI pacemakers and transvenous VVI pacemakers compare in a contemporaneous Medicare population?

Mar 6, 2024 | healio.com | Scott Buzby |Richard Smith |Mikhael F. El-Chami

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Long-term real-world data showed favorable performance of a leadless permanent pacemaker implant. The 5-year rates of major complications and need for system revision were low, with no removals for infection.

Dec 17, 2023 | onlinelibrary.wiley.com | Mikhael F. El-Chami

INVITED EDITORIAL Same day discharge after transvenous lead extraction: Balancing safety and efficiency Mikhael F. El-Chami MD,  Corresponding Author Mikhael F. El-Chami MD Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia, USA Correspondence Mikhael F. El-Chami, MD, FHRS, Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, 550 Peachtree St NE, Atlanta, GA 30308, USA.

Oct 1, 2023 | jacc.org | Raul Weiss |Bradley P. Knight |Mikhael F. El-Chami |Johan D. Aasbo

1. "Implant and midterm outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: the EFFORTLESS study". J Am Coll Cardiol . 2017;70:830-841. 2. "Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator". Circulation . 2013;128:944-953. 3. "Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry". Eur Heart J . 2014;35:1657-1665. 4. "Subcutaneous or transvenous defibrillator therapy".

May 3, 2023 | jacc.org | Michael Gold |Mikhael F. El-Chami |Martin Burke |Gaurav A. Upadhyay

JACC Journals › JACC › Archives › Vol. 82 No. 5 AbstractBackgroundThe subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to avoid complications related to transvenous implantable cardioverter-defibrillator (TV-ICD) leads. Device safety and efficacy were demonstrated previously with atypical clinical patients or limited follow-up.